An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This multicenter, prospective, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in first-line therapy in elderly patients with metastatic colorectal cancer. Data will be collected from eligible patients for24 months.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
75 Years and older (Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Elderly patients with metastatic colorectal cancer initiating first-line treatment with Avastin
Adult patients, >/= 75 years of age
Metastatic colorectal cancer
Initiating Avastin first-line therapy in combination with chemotherapy
Previous Avastin therapy
Patient participating in a clinical study evaluating a cytotoxic anti-cancer therapy and/or an investigational new drug